Maurizio Gallieni

Prof. Maurizio Gallieni

Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Department of Clinical and Biomedical Sciences ‘Luigi Sacco’, University of Milan, Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
JSJürg Schmidli
Jürg Schmidli
MWMatthias K. Widmer
Matthias K. Widmer
CBCarlo Basile
Carlo Basile
GDGianmarco de Donato
Gianmarco de Donato
MGMaurizio Gallieni
Maurizio Gallieni
RRRamon Roca-Tey
Ramon Roca-Tey

1 May 2016 in The Lancet Global Health
Verified
Journal Article
Open access
Bogdan Ene-IordacheBogdan Ene-Iordache
Bogdan Ene-Iordache
NPNorberto Perico
Norberto Perico
BBBoris Bikbov
Boris Bikbov
SCSergio Carminati
Sergio Carminati
ARAndrea Remuzzi
Andrea Remuzzi
Giuseppe RemuzziGiuseppe Remuzzi
Giuseppe Remuzzi
Chronic kidney disease is an important cause of global mortality and morbidity. Data for epidemiological features of chronic kidney disease and its risk factors are limited for low-income and middle-income countries. The International Society of Nephrology's Kidney Disease Data Center (ISN-KDDC) aimed to assess the prevalence and awareness of chronic kidney disease and its risk factors, and to investigate the risk of cardiovascular disease, in countries of low and middle income. We did a cross-sectional study in 12 countries from six world regions: Bangladesh, Bolivia, Bosnia and Herzegovina, China, Egypt, Georgia, India, Iran, Moldova, Mongolia, Nepal, and Nigeria. We analysed data from screening programmes in these countries, matching eight general and four high-risk population cohorts collected in the ISN-KDDC database. High-risk cohorts were individuals at risk of or with a diagnosis of either chronic kidney disease, hypertension, diabetes, or cardiovascular disease. Participants completed a self-report questionnaire, had their blood pressure measured, and blood and urine samples taken. We defined chronic kidney disease according to modified KDIGO (Kidney Disease: Improving Global Outcomes) criteria; risk of cardiovascular disease development was estimated with the Framingham risk score. 75,058 individuals were included in the study. The prevalence of chronic kidney disease was 14·3% (95% CI 14·0-14·5) in general populations and 36·1% (34·7-37·6) in high-risk populations. Overall awareness of chronic kidney disease was low, with 409 (6%) of 6631 individuals in general populations and 150 (10%) of 1524 participants from high-risk populations aware they had chronic kidney disease. Moreover, in the general population, 5600 (44%) of 12,751 individuals with hypertension did not know they had the disorder, and 973 (31%) of 3130 people with diabetes were unaware they had that disease. The number of participants at high risk of cardiovascular disease, according to the Framingham risk score, was underestimated compared with KDIGO guidelines. For example, all individuals with chronic kidney disease should be considered at high risk of cardiovascular disease, but the Framingham risk score detects only 23% in the general population, and only 38% in high-risk cohorts. Prevalence of chronic kidney disease was high in general and high-risk populations from countries of low and middle income. Moreover, awareness of chronic kidney disease and other non-communicable diseases was low, and a substantial number of individuals who knew they were ill did not receive treatment. Prospective programmes with repeat testing are needed to confirm the diagnosis of chronic kidney disease and its risk factors. Furthermore, in general, health-care workforces in countries of low and middle income need strengthening. International Society of Nephrology.

1 July 2019 in Kidney International
Verified
Journal Article
Open access
CCChristoper T. Chan
Christoper T. Chan
PBPeter J. Blankestijn
Peter J. Blankestijn
LDLaura M. Dember
Laura M. Dember
MGMaurizio Gallieni
Maurizio Gallieni
DHDavid C.H. Harris
David C.H. Harris
EZElena Zakharova
Elena Zakharova
Globally, the number of patients undergoing maintenance dialysis is increasing, yet throughout the world there is significant variability in the practice of initiating dialysis. Factors such as availability of resources, reasons for starting dialysis, timing of dialysis initiation, patient education and preparedness, dialysis modality and access, as well as varied "country-specific" factors significantly affect patient experiences and outcomes. As the burden of end-stage kidney disease (ESKD) has increased globally, there has also been a growing recognition of the importance of patient involvement in determining the goals of care and decisions regarding treatment. In January 2018, KDIGO (Kidney Disease: Improving Global Outcomes) convened a Controversies Conference focused on dialysis initiation, including modality choice, access, and prescription. Here we present a summary of the conference discussions, including identified knowledge gaps, areas of controversy, and priorities for research. A major novel theme represented during the conference was the need to move away from a "one-size-fits-all" approach to dialysis and provide more individualized care that incorporates patient goals and preferences while still maintaining best practices for quality and safety. Identifying and including patient-centered goals that can be validated as quality indicators in the context of diverse health care systems to achieve equity of outcomes will require alignment of goals and incentives between patients, providers, regulators, and payers that will vary across health care jurisdictions.

21 October 2008 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Closed access
PDF file
MGMaurizio Gallieni
Maurizio Gallieni
MPMauro Pittiruti
Mauro Pittiruti
RBRoberto Biffi
Roberto Biffi

1 August 2005 in Kidney International
Verified
Journal Article
Closed access
Mario CozzolinoMario Cozzolino
Mario Cozzolino
DBDiego Brancaccio
Diego Brancaccio
MGMaurizio Gallieni
Maurizio Gallieni
ESEduardo Slatopolsky
Eduardo Slatopolsky

1 July 2008 in The Journal of Vascular Access
Verified
Journal Article
Closed access
PDF file
Jan MalikJan Malik
Jan Malik
VTVladimír Tuka
Vladimír Tuka
ZKZ. Kasalova
Z. Kasalova
ECE. Chytilova
E. Chytilova
MSM. Slavikova
M. Slavikova
MGMaurizio Gallieni
Maurizio Gallieni
Distal hypoperfusion ischemic syndrome (DHIS), commonly referred to as hand ischemia or “steal” after dialysis access placement, occurs in 5–10% of cases when the brachial artery is used, or 10 times that of wrist arteriovenous fistulas (AVFs) using the radial artery. It is typically seen in elderly women with diabetes, and may carry severe morbidity including tissue or limb loss if not recognized and treated. Three distinct etiologies include (1) blood flow restriction to the hand from arterial occlusive disease either proximal or distal to the AV access anastomosis, (2) excess blood flow through the AV fistula conduit (true steal), and (3) lack of vascular (arterial) adaptation or collateral flow reserve (ie atherosclerosis) to the increased flow demand from the AV conduit. These three causes of steal may occur alone or in concert. The diagnosis of steal is based on an accurate history and physical examination and confirmed with tests including an arteriogram, duplex Doppler ultrasound (DDU) evaluation with finger pressures and waveform analysis. Treatment of steal includes observation of developing symptoms in mild cases. Balloon angioplasty is the appropriate intervention for an arterial stenosis. At least three distinct surgical corrective procedures exist to counteract the pathophysiology of steal. The ultimate treatment strategy depends on severity of symptoms, the extent of patient co-morbidity, and the local dialysis access technical team support and skills available.